Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Schmalzing

Showing results (111-120 of 136) with videos related to

Pageof 14
Sort By:
Plos One|May 29, 2019
New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II studyMatthias Englbrecht, Rieke Alten, Martin Aringer, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Whole-Body [<sup>18</sup>F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic DiseaseMatthias Fröhlich, Sebastian Serfling, Takahiro Higuchi, et al.
Therapeutic Advances in Musculoskeletal Disease|June 29, 2026
Association of an app-based intervention with improvements in mobility, trunk muscle strength and patient-reported disease activity in axial spondyloarthritis: a 24-week pre-post studyPatrick-Pascal Strunz, Marc Schmalzing, Amelie Wüst, et al.
Arthritis Care & Research|August 3, 2016
Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated ChallengeMatthias Englbrecht, Rieke Alten, Martin Aringer, et al.
Zeitschrift Fur Rheumatologie|April 27, 2026
Diana Ernst, , Thomas Dörner, et al.
Frontiers in Immunology|June 7, 2024
Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR databasePatrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, et al.
Rheumatology International|August 13, 2024
Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR networkPatrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, et al.
Zeitschrift Fur Rheumatologie|March 19, 2026
[Proposal of the rheumatology societies in the D-A-CH region for a uniform German nomenclature for Sjögren's disease]Diana Ernst, , Thomas Dörner, et al.
Rheumatology (Oxford, England)|April 16, 2026
Treatment of systemic sclerosis-associated pulmonary hypertension with and without interstitial lung disease and its impact on survival: a large cohort study of the German network for systemic sclerosisMarc Schmalzing, Pia Moinzadeh, Jithmi Weliwitage, et al.
Zeitschrift Fur Rheumatologie|November 11, 2025
[S2k guidelines on diagnostics and treatment of systemic sclerosis : Abridged version]Jörg C Henes, Swantje Arndt, Melanie Berger, et al.
Pageof 14

Showing results (111-120 of 136) with videos related to

Sort By:
Pageof 14
Plos One|May 29, 2019
New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II studyMatthias Englbrecht, Rieke Alten, Martin Aringer, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Whole-Body [<sup>18</sup>F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic DiseaseMatthias Fröhlich, Sebastian Serfling, Takahiro Higuchi, et al.
Therapeutic Advances in Musculoskeletal Disease|June 29, 2026
Association of an app-based intervention with improvements in mobility, trunk muscle strength and patient-reported disease activity in axial spondyloarthritis: a 24-week pre-post studyPatrick-Pascal Strunz, Marc Schmalzing, Amelie Wüst, et al.
Arthritis Care & Research|August 3, 2016
Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated ChallengeMatthias Englbrecht, Rieke Alten, Martin Aringer, et al.
Zeitschrift Fur Rheumatologie|April 27, 2026
Diana Ernst, , Thomas Dörner, et al.
Frontiers in Immunology|June 7, 2024
Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR databasePatrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, et al.
Rheumatology International|August 13, 2024
Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR networkPatrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, et al.
Zeitschrift Fur Rheumatologie|March 19, 2026
[Proposal of the rheumatology societies in the D-A-CH region for a uniform German nomenclature for Sjögren's disease]Diana Ernst, , Thomas Dörner, et al.
Rheumatology (Oxford, England)|April 16, 2026
Treatment of systemic sclerosis-associated pulmonary hypertension with and without interstitial lung disease and its impact on survival: a large cohort study of the German network for systemic sclerosisMarc Schmalzing, Pia Moinzadeh, Jithmi Weliwitage, et al.
Zeitschrift Fur Rheumatologie|November 11, 2025
[S2k guidelines on diagnostics and treatment of systemic sclerosis : Abridged version]Jörg C Henes, Swantje Arndt, Melanie Berger, et al.
Pageof 14